Search Results - "Labaki C"

3136O AI-generated synthetic cohorts for accelerated clinical trial design and collaboration: Data from 19,000 patients (Pts) with metastatic breast cancer (MBC).

Authors: Saad, E. Labaki, C. Bakouny, Z. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS673-S674. 2p.

118P A framework for the evaluation of intermediate clinical endpoints of overall survival in real-world clinical data: Applications to metastatic breast cancer.

Authors: Labaki, C. Bakouny, Z. Sanglier, T. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS250-S251. 2p.

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.

Authors: Bakouny, Z. Labaki, C. Bhalla, S. et al.

Source: Annals of Oncology. Aug2022, Vol. 33 Issue 8, p836-844. 9p.

COVID-19 vaccination and breakthrough infections in patients with cancer.

Authors: Schmidt, A.L. Labaki, C. Hsu, C.-Y. et al.

Source: Annals of Oncology. Mar2022, Vol. 33 Issue 3, p340-346. 7p.

O 068 - The variation of lateral and posterior coverage of the femoral head by the acetabulum during walking influences stability during gait.

Authors: Labaki, C. Karam, A. Mjaess, G. et al.

Source: Gait & Posture. Sep2018:Supplement 1, Vol. 65, p139-141. 3p.

O 067 - How does the variation of the 3D orientation of the acetabulum during walking influence hip kinematics?

Authors: Mjaess, G. Labaki, C. Karam, A. et al.

Source: Gait & Posture. Sep2018:Supplement 1, Vol. 65, p136-138. 3p.

O 028 - How do 3D skeletal parameters influence kinetics?

Authors: Karam, A. Labaki, C. Mjaess, G. et al.

Source: Gait & Posture. Sep2018:Supplement 1, Vol. 65, p57-59. 3p.

P 154 - How do 3D skeletal parameters and demographics determine kinematic adaptation from normal to fast speed gait?

Authors: Mjaess, G. Karam, A. Labaki, C. et al.

Source: Gait & Posture. Sep2018:Supplement 1, Vol. 65, p490-492.

252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.

Authors: Labaki, C. Bakouny, Z. Sanglier, T. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS652-S652. 1p.

2601P Peripheral and tumor cytokines in exceptional responders to immunotherapy: Results from a phase III trial.

Authors: Saliby, R.M. Machaalani, M. Labaki, C. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1395-S1396. 2p.

502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer.

Authors: Bakouny, Z. Grover, P. Labaki, C. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS772-S773. 2p.

3120eP Brain metastasis (BM) from bladder cancer (BCa) in the era of Antibody-Drug Conjugates (ADCs): Impact on survival from a large cohort.

Authors: El Masri, J. Ascione, L. Moura Barrios, P. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1616-S1617. 2p.

2666eP Genomic determinants of primary resistance to immune checkpoint inhibition in metastatic renal cell carcinoma.

Authors: Eid, M. Saleh, M. Ascione, L. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1425-S1426. 2p.

132P Genomic determinants of leukocyte homeostasis predict responses to immune checkpoint blockade (ICB) monotherapy versus combination therapy in patients (pts) with cancer.

Authors: Saleh, M. Saad, E. Machaalani, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS256-S257. 2p.

1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study.

Authors: Saliby, R.M. Xie, W. Wells, J.C. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1021-S1022. 2p.

501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19.

Authors: Halabi, S. Luo, B. Dzimitrowicz, H. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS771-S772. 2p.

116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis.

Authors: El Zarif, T. Pond, G. Nassar, A. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS591-S592. 2p.

CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Authors: Lemelin A Maj D Takemura K et al.

Source: Clinical genitourinary cancer [Clin Genitourin Cancer] 2025 Dec; Vol. 23 (6), pp. 102431. Date of Electronic Publication: 2025 Sep 09.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

Humoral immune responses to the second dose of a COVID-19 mRNA vaccine in cancer patients undergoing treatment.

Authors: Dang CM Kemp TJ Roche N et al.

Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2570963. Date of Electronic Publication: 2025 Oct 14.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment.

Authors: Xue H Kemp TJ Li C et al.

Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2589647. Date of Electronic Publication: 2025 Nov 27.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE